LncRNA ANRIL/miR-7-5p/TCF4 axis contributes to the progression of T cell acute lymphoblastic leukemia.
ANRIL
T-ALL
lncRNAs
miR-7-5p
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
12
2019
accepted:
24
06
2020
entrez:
28
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Antisense non-coding RNA in the INK4 locus (ANRIL) is of great importance in cell biological behaviors, and ANRIL functions in many kinds of cancers including leukemia. However, the mechanism of ANRIL in the progression of T-cell acute lymphoblastic leukemia (T-ALL) has not been clarified clearly. qRT-PCR was performed to detect ANRIL expression in T-ALL samples. T-ALL cell lines (MOLT4, CCRF-CEM and KOPT-K1) were used as the cell models. The function of ANRIL on T-ALL cells was investigated by CCK-8 assays, Transwell assays, and apoptosis experiments in vitro. qRT-PCR, Western blot, luciferase reporter assay and RIP assay were used to confirm the interactions between ANRIL and miR-7-5p, miR-7-5p and its target gene transcription factor 4 (TCF4). ANRIL was significantly up-regulated in T-ALL samples. Its knockdown markedly inhibited viability, migration and invasion of T-ALL cells, but its overexpression exerted the opposite effects. TCF4 was proved to be a target gene of miR-7-5p. ANRIL down-regulated miR-7-5p via sponging it and in turn up-regulated TCF4. LncRNA ANRIL can modulate malignant phenotypes of T-ALL cells, possibly by regulating miR-7-5p/TCF4 axis, and it serves as a potential therapeutic target for T-ALL.
Sections du résumé
BACKGROUND
BACKGROUND
Antisense non-coding RNA in the INK4 locus (ANRIL) is of great importance in cell biological behaviors, and ANRIL functions in many kinds of cancers including leukemia. However, the mechanism of ANRIL in the progression of T-cell acute lymphoblastic leukemia (T-ALL) has not been clarified clearly.
METHODS
METHODS
qRT-PCR was performed to detect ANRIL expression in T-ALL samples. T-ALL cell lines (MOLT4, CCRF-CEM and KOPT-K1) were used as the cell models. The function of ANRIL on T-ALL cells was investigated by CCK-8 assays, Transwell assays, and apoptosis experiments in vitro. qRT-PCR, Western blot, luciferase reporter assay and RIP assay were used to confirm the interactions between ANRIL and miR-7-5p, miR-7-5p and its target gene transcription factor 4 (TCF4).
RESULTS
RESULTS
ANRIL was significantly up-regulated in T-ALL samples. Its knockdown markedly inhibited viability, migration and invasion of T-ALL cells, but its overexpression exerted the opposite effects. TCF4 was proved to be a target gene of miR-7-5p. ANRIL down-regulated miR-7-5p via sponging it and in turn up-regulated TCF4.
CONCLUSIONS
CONCLUSIONS
LncRNA ANRIL can modulate malignant phenotypes of T-ALL cells, possibly by regulating miR-7-5p/TCF4 axis, and it serves as a potential therapeutic target for T-ALL.
Identifiants
pubmed: 32714094
doi: 10.1186/s12935-020-01376-8
pii: 1376
pmc: PMC7376839
doi:
Types de publication
Journal Article
Langues
eng
Pagination
335Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors announce that there are no competing interests.
Références
Med Sci Monit Basic Res. 2019 May 01;25:128-138
pubmed: 31040265
BMC Cancer. 2018 Sep 24;18(1):919
pubmed: 30249208
J Exp Clin Cancer Res. 2019 Apr 15;38(1):163
pubmed: 30987661
Blood. 2009 Apr 23;113(17):4016-26
pubmed: 19131553
Cancer Res. 2013 Sep 15;73(18):5609-12
pubmed: 24014594
Mol Ther Nucleic Acids. 2018 Dec 7;13:121-132
pubmed: 30290304
Am J Cancer Res. 2018 Nov 01;8(11):2296-2310
pubmed: 30555745
Immunity. 2007 Feb;26(2):227-39
pubmed: 17306568
Cancers (Basel). 2019 May 06;11(5):
pubmed: 31064074
Int J Mol Sci. 2019 Apr 18;20(8):
pubmed: 31003545
Oncotarget. 2016 Sep 6;7(36):57903-57918
pubmed: 27507052
PLoS Med. 2016 Dec 20;13(12):e1002200
pubmed: 27997540
Biomed Pharmacother. 2019 Aug;116:108836
pubmed: 31004838
Virol Sin. 2019 Jun;34(3):278-286
pubmed: 30953292
Leuk Res. 2011 Aug;35(8):1052-9
pubmed: 21414664
J Exp Clin Cancer Res. 2019 Feb 20;38(1):92
pubmed: 30786928
Cell. 2006 Nov 3;127(3):469-80
pubmed: 17081971
Biochem Pharmacol. 2010 Dec 1;80(11):1641-9
pubmed: 20797387
J Exp Clin Cancer Res. 2019 Apr 26;38(1):179
pubmed: 31027497
Dev Biol. 2005 Jul 1;283(1):226-39
pubmed: 15907834
Leukemia. 2019 Jun;33(6):1373-1386
pubmed: 30575820
J Virol. 2018 Nov 27;92(24):
pubmed: 30258009
Wiley Interdiscip Rev RNA. 2019 Sep;10(5):e1537
pubmed: 31007002
Cancer Cell Int. 2019 Apr 24;19:108
pubmed: 31049030
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):590-594
pubmed: 28689002
J Biol Chem. 2019 May 10;294(19):7692-7710
pubmed: 30885941
Nat Rev Cancer. 2010 Oct;10(10):683-95
pubmed: 20814421
Int J Biochem Cell Biol. 2020 Feb;119:105666
pubmed: 31830533
Front Endocrinol (Lausanne). 2019 Apr 08;10:207
pubmed: 31024447
Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):372-378
pubmed: 28986256
PLoS One. 2016 Mar 25;11(3):e0152407
pubmed: 27014877
Aging (Albany NY). 2019 Mar 10;11(5):1389-1403
pubmed: 30853664
Biochem Biophys Res Commun. 2018 May 23;499(4):829-835
pubmed: 29621542
Anticancer Res. 2015 Oct;35(10):5377-82
pubmed: 26408699
J Hematol Oncol. 2015 May 29;8(1):57
pubmed: 27391317
Cell Rep. 2013 Oct 31;5(2):471-81
pubmed: 24120864
Exp Cell Res. 2018 Jul 15;368(2):194-201
pubmed: 29723509
Anticancer Res. 2015 Oct;35(10):5667-70
pubmed: 26408741
Oncotarget. 2016 May 31;7(22):31663-80
pubmed: 27203220
Mech Ageing Dev. 2017 Oct;167:16-23
pubmed: 28888705
Cancer. 2015 Aug 1;121(15):2517-28
pubmed: 25891003
Cancer Metastasis Rev. 2018 Mar;37(1):83-105
pubmed: 29247341
Haematologica. 2014 Dec;99(12):e257-9
pubmed: 25150259
Leukemia. 2015 Jun;29(6):1267-78
pubmed: 25482131
Nat Commun. 2018 Dec 14;9(1):5321
pubmed: 30552326
Blood Cancer J. 2017 Jun 30;7(6):e577
pubmed: 28665419
Mol Cancer. 2018 Aug 22;17(1):127
pubmed: 30134922
Mol Cancer. 2017 Jun 21;16(1):107
pubmed: 28637507
Pediatr Blood Cancer. 2018 Jun;65(6):e26989
pubmed: 29418064
BMC Cancer. 2018 Oct 29;18(1):1048
pubmed: 30373600
PLoS One. 2018 Jul 5;13(7):e0200215
pubmed: 29975781
Cancer Sci. 2019 Jan;110(1):256-268
pubmed: 30460757
Small. 2018 Jan;14(1):
pubmed: 29148623
Methods Mol Biol. 2018;1699:45-66
pubmed: 29086367
Exp Cell Res. 2019 Jul 15;380(2):198-204
pubmed: 31004581